Use of Cerebrolysin in combination with high‐dose aspirin antithrombotic treatment of ischemic stroke: A case report

This clinical case is showing a potential synergistic neuroprotective interaction of Cerebrolysin and high doses of aspirin. The case describes the significant recovery of neurological deficits in a patient with moderate ischemic stroke caused by right posterior cerebral artery thrombosis after treatment with Cerebrolysin in combination with aspirin

Download Full-text

Effect of High-Dose Aspirin on CYP2E1 Activity in Healthy Subjects Measured Using Chlorzoxazone as a Probe

The Journal of Clinical Pharmacology ◽

10.1177/0091270005282635 ◽

2006 ◽

Vol 46 (1) ◽

pp. 109-114 ◽

Cited By ~ 7

Author(s):

Ji-Young Park ◽

Kyoung-Ah Kim ◽

Pil-Whan Park ◽

Jong-Myung Ha

Keyword(s):

Healthy Subjects ◽

High Dose ◽

Dose Aspirin ◽

Cyp2e1 Activity ◽

High Dose Aspirin

Download Full-text

High-dose aspirin appears to be associated with a high rate of haemorrhagic events,

Inpharma Weekly ◽

10.2165/00128413-200515090-00046 ◽

2005 ◽

Vol &NA; (1509) ◽

pp. 20

Author(s):

&NA;

Keyword(s):

High Rate ◽

High Dose ◽

Dose Aspirin ◽

High Dose Aspirin

Download Full-text

High-dose aspirin is neuroprotective in a rat focal ischemia model

Brain Research ◽

10.1016/j.brainres.2003.11.049 ◽

2004 ◽

Vol 998 (2) ◽

pp. 237-242 ◽

Cited By ~ 18

Author(s):

Christian Berger ◽

Feng Xia ◽

Wolf-Ruediger Schabitz ◽

Stefan Schwab ◽

Armin Grau

Keyword(s):

Focal Ischemia ◽

High Dose ◽

Dose Aspirin ◽

High Dose Aspirin

Download Full-text

ROLE OF HIGH DOSE ASPIRIN IN MODULATING HYPERLIPIDEMIA AND HYPERGLYCEMIA

Journal of Applied Pharmacy ◽

10.21065/19204159.2.112 ◽

2010 ◽

Vol 2 ◽

pp. 112-119

Author(s):

Bashir Ahmad . ◽

Uzma Saleem . ◽

Farman Matloob Khan . ◽

Alia Erum . ◽

Maqsood Alam . ◽

...

Keyword(s):

High Dose ◽

Dose Aspirin ◽

High Dose Aspirin

Download Full-text

Dose-dependent roles of aspirin and other non-steroidal anti-inflammatory drugs in abnormal bone remodeling and skeletal regeneration

Cell & Bioscience ◽

10.1186/s13578-019-0369-9 ◽

2019 ◽

Vol 9 (1) ◽

Cited By ~ 6

Author(s):

Yong Xie ◽

Meng Pan ◽

Yanpan Gao ◽

Licheng Zhang ◽

Wei Ge ◽

...

Keyword(s):

Bone Formation ◽

Bone Remodeling ◽

Low Dose ◽

High Dose ◽

Dose Aspirin ◽

Low Dose Aspirin ◽

Inflammatory Drugs ◽

Anti Inflammatory ◽

Dose Dependent ◽

High Dose Aspirin

AbstractThe failure of remodeling process that constantly regenerates effete, aged bone is highly associated with bone nonunion and degenerative bone diseases. Numerous studies have demonstrated that aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) activate cytokines and mediators on osteoclasts, osteoblasts and their constituent progenitor cells located around the remodeling area. These cells contribute to a complex metabolic scenario, resulting in degradative or synthetic functions for bone mineral tissues. The spatiotemporal effects of aspirin and NSAIDs in the bone remodeling are controversial according the specific therapeutic doses used for different clinical conditions. Herein, we review in vitro, in vivo, and clinical studies on the dose-dependent roles of aspirin and NSAIDs in bone remodeling. Our results show that low-dose aspirin (< 100 μg/mL), which is widely recommended for prevention of thrombosis, is very likely to be benefit for maintaining bone mass and qualities by activation of osteoblastic bone formation and inhibition of osteoclast activities via cyclooxygenase-independent manner. While, the roles of high-dose aspirin (150–300 μg/mL) and other NSAIDs in bone self-regeneration and fracture-healing process are difficult to elucidate owing to their dual effects on osteoclast activity and bone formation of osteoblast. In conclusion, this study highlighted the potential clinical applications of low-dose aspirin in abnormal bone remodeling as well as the risks of high-dose aspirin and other NSAIDs for relieving pain and anti-inflammation in fractures and orthopedic operations.

Download Full-text

Kawasaki Disease Presenting as Acute Acalculous Cholecystitis

Clinical Practice and Cases in Emergency Medicine ◽

10.5811/cpcem.2019.8.44255 ◽

2019 ◽

Vol 3 (4) ◽

pp. 383-386 ◽

Cited By ~ 2

Author(s):

Demis Lipe ◽

Lindsey Bridges

Keyword(s):

Coronary Artery ◽

Kawasaki Disease ◽

Acalculous Cholecystitis ◽

Acute Acalculous Cholecystitis ◽

High Dose ◽

Coronary Artery Aneurysms ◽

Abdominal Symptoms ◽

Dose Aspirin ◽

Serious Disease ◽

High Dose Aspirin

Acute acalculous cholecystitis (AAC) is a rare, potentially serious disease that has been associated with Kawasaki disease (KD) in children. Studies suggest that patients presenting with severe abdominal symptoms secondary to KD have increased resistance to intravenous immunoglobulin (IVIG), and a higher rate of coronary artery aneurysms. We describe an eight-year-old boy who presented to the emergency department with severe abdominal pain and was diagnosed with AAC and KD. He was treated with IVIG and high-dose aspirin, achieving good response with complete symptom resolution. He had no coronary artery aneurysms or further complications and was discharged after three days.

Download Full-text

Prolonged aspirin inhibition of anodal vasodilation is not due to the trafficking delay of neural mediators

AJP Regulatory Integrative and Comparative Physiology ◽

10.1152/ajpregu.00742.2002 ◽

2003 ◽

Vol 285 (1) ◽

pp. R155-R161 ◽

Cited By ~ 6

Author(s):

S. Durand ◽

B. Fromy ◽

M. Tartas ◽

A. Jardel ◽

J. L. Saumet ◽

...

Keyword(s):

Time Course ◽

Nerve Endings ◽

High Dose ◽

Current Application ◽

Cutaneous Vasodilation ◽

Dose Aspirin ◽

Proximal Site ◽

Time Required ◽

Distal Site ◽

High Dose Aspirin

We previously reported that forearm vasodilation to a delivered all-at-once over 5 min or a 1-min repeated monopolar anodal 0.10-mA current application is aspirin sensitive and that a single high-dose aspirin exerts a long-lived effect in the former case. We hypothesized that 1) in the latter case, the effect of aspirin would also be long lived and 2) the time required to resupply nerve endings with unblocked cyclooxygenase through axonal transport could explain this phenomenon. We studied the time course for the recovery of vasodilation to repeated current application after placebo or 1-g aspirin treatment. We then searched for a difference at a proximal vs. distal site in the recovery of the response. Aspirin abolished current-induced vasodilation at 2 h, 10 h, and 3 days, with a progressive recovery thereafter, but no difference between distal and proximal site was observed for the recovery of the response. This suggests that, although neural cyclooxygenase could participate in the response, the time course of aspirin inhibition of current-induced cutaneous vasodilation is not due to the time required through neural transport to resupply nerve endings with unblocked proteins.

Download Full-text

What dose of aspirin should be used in the initial treatment of Kawasaki disease? A meta-analysis

Rheumatology ◽

10.1093/rheumatology/keaa050 ◽

2020 ◽

Vol 59 (8) ◽

pp. 1826-1833

Author(s):

Xinyi Jia ◽

Xiao Du ◽

Shuxian Bie ◽

Xiaobing Li ◽

Yunguang Bao ◽

...

Keyword(s):

Kawasaki Disease ◽

Random Effects ◽

Initial Treatment ◽

Low Dose ◽

Cochrane Library ◽

High Dose ◽

Random Effects Model ◽

Dose Aspirin ◽

Low Dose Aspirin ◽

High Dose Aspirin

Abstract Objective The use of IVIG plus high- or low-dose aspirin for the initial treatment of Kawasaki disease remains controversial. The aim of this study was to evaluate the efficacy of IVIG plus high-dose aspirin compared with IVIG plus low-dose aspirin in the treatment of Kawasaki disease. Methods Studies related to aspirin therapy for Kawasaki disease were selected by searching the databases of Medline (PubMed), Embase and the Cochrane Library before March 2019. Statistical analyses were performed by using a Review Manager Software package and STATA v.15.1. Results Eight retrospective cohort studies, characterizing 12 176 patients, were analysed. Overall, no significant difference was found in the incidence of coronary artery abnormalities between the high- and low-dose aspirin groups [relative risk (RR) 1.15; 95% CI: 0.93, 1.43; P = 0.19; random-effects model]. The patients treated with high-dose aspirin had slightly faster resolution of fever [mean difference (MD) −0.30; 95% CI: −0.58, −0.02; P = 0.04; random-effects model]. but the rates of IVIG resistance (RR, 1.26; 95% CI: 0.55, 2.92; P = 0.59; random-effects model) and days in hospital (MD, 0.22; 95% CI: −0.93, 1.37; P = 0.71; random-effects model) were similar between the two groups. Conclusion Low-dose aspirin plus IVIG might be as effective as high-dose aspirin plus IVIG for the initial treatment of Kawasaki disease. Considering that high-dose aspirin may cause more adverse reactions than low-dose aspirin, low-dose aspirin plus IVIG should be recommended as the first-line therapy in the initial treatment of Kawasaki disease.

Download Full-text